Cardio Diagnostics Holdings, Inc. (CDIO) stock
CDIONasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31Also trades as CDIOW
$1.87−0.05 (-2.60%)
Close on Nov 12, 2026Market cap $5.53MP/E –Yield –
Cardio Diagnostics r&d expenses
Research and development expenses are spending on new products and technology.
Cardio Diagnostics's R&D Expenses for the twelve months ending Sep 30, 2026 was $621.80K. For fiscal 2025 it was $641.21K, up 181.3% from the year before. The highest annual figure on record is $641.21K in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $641.21K | +181.3% |
| FY2024 | Dec 31, 2024 | $227.97K | +57.0% |
| FY2023 | Dec 31, 2023 | $145.18K | +258.9% |
| FY2022 | Dec 31, 2022 | $40.45K | +28.5% |
| FY2021 | Dec 31, 2021 | $31.47K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $174.25K | +46.7% |
| Q2 FY2026 | Jun 30, 2026 | $162.93K | -20.4% |
| Q1 FY2026 | Mar 31, 2026 | $129.78K | +2373.3% |
| Q4 FY2025 | Dec 31, 2025 | $154.84K | +2027.0% |
| Q1 FY2025 | Mar 31, 2025 | $118.78K | +995.8% |
| Q4 FY2024 | Dec 31, 2024 | $204.60K | +2630.9% |
| Q3 FY2024 | Sep 30, 2024 | $5.25K | -86.4% |
| Q2 FY2024 | Jun 30, 2024 | $7.28K | -40.9% |
| Q1 FY2024 | Mar 31, 2024 | $10.84K | -87.5% |
| Q4 FY2023 | Dec 31, 2023 | $7.49K | +48.6% |
| Q3 FY2023 | Sep 30, 2023 | $38.71K | +3325.5% |
| Q2 FY2023 | Jun 30, 2023 | $12.32K | – |
| Q1 FY2023 | Mar 31, 2023 | $86.67K | – |
| Q2 FY2022 | Jun 30, 2022 | $5.04K | – |
| Q1 FY2022 | Mar 31, 2022 | $1.13K | – |
See a number that looks wrong?